About: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 May 1997

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в травні 1997 (uk) article scientifique publié en 1997 (fr) im Mai 1997 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en mayu de 1997 (ast) scientific article published on 01 May 1997 (en)
publication date	wds:Q73368715-A4FA3E5C-BA66-4ECB-B8E4-3F7CD8E1F048
publication date	1997-05-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73368715-DAD26A84-7504-4EFC-94C4-E976D37E1BB4
language of work or name	English
author name string	wds:Q73368715-0390A197-2228-4621-A254-723BB5730410 wds:Q73368715-1E9FA9CE-129F-4F73-AD7B-6CB6A3B9E906 wds:Q73368715-46BBDB78-50C9-4665-9A2A-7B80C58C4154 wds:Q73368715-9198EDC6-8F44-4FF9-872C-E3707B465A26 wds:Q73368715-C8ED1E16-1FD5-4F3A-917F-B3DC686CC041 wds:Q73368715-DD74B23D-532D-4CDF-B617-2F6C5EC6C3D5 wds:Q73368715-E08D2623-8146-4EFC-8D7B-071314A25C00 wds:Q73368715-F13633E3-EADB-4658-8555-73165F7D2A57
author name string	H Hansen S Kaplan J Verweij A Ardizzoni P Dombernowsky J Wanders T Gamucci B Schaefer
rdfs:label	Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and (en) Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and (nl)
skos:prefLabel	Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and (en) Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and (nl)
name	Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and (en) Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and (nl)
author	wds:Q73368715-0E681AF0-F00D-4CF6-A31B-26CCE2A76718 wds:Q73368715-5B906D79-70F9-450C-BB41-949DB558C735
author	Giuseppe Giaccone Pieter E Postmus
title	wds:Q73368715-B1DB67B9-F4F4-42F9-A2E4-B5BA9B0416D9
title	Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group (en)
page(s)	wds:Q73368715-CEEB23B3-88BB-4CE8-9EE9-719FF06D6DEF
page(s)	2090-2096
instance of	wds:Q73368715-3A2D5A94-0085-4147-8D98-7519796DBB33
instance of	scholarly article
main subject	wds:Q73368715-8A66A51A-0AC6-4FF3-AEDE-430AC51DD72B
main subject	lung cancer
PubMed ID	wds:Q73368715-EC25CAEA-80EC-40F1-8DBA-D4245D135EEF
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/9164222
PubMed ID	9164222
published in	wds:Q73368715-7AA61A8C-585A-48AB-9C84-BD7E8AFD96B3
published in	Journal of Clinical Oncology
issue	wds:Q73368715-713AF54E-3281-46D4-BE8A-A6ED13559DD3
volume	wds:Q73368715-277090BF-9452-41F6-99B1-3179ADF0C2EC
issue	5
volume	15
DOI	wds:Q73368715-83AF5694-7BAC-4C4F-85E5-1FC08171A0F3
DOI	http://dx.doi.org/10.1200/JCO.1997.15.5.2090
DOI	10.1200/JCO.1997.15.5.2090
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73368715
is cites work of	A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). Combination of HDAC and topoisomerase inhibitors in small cell lung cancer Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. a multicentre phase II study A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer Single-agent gemcitabine in patients with resistant small-cell lung cancer The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer Chemotherapy for brain metastases of lung cancer: a review Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeutics Small-cell lung cancer Second-line treatment of small-cell lung cancer Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan Small cell lung cancer (SCLC): no treatment advances in recent years Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: a study of the EORTC Early Clinical Studies Group (ECSG). The camptothecins. A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study Topotecan: a review of its efficacy in small cell lung cancer Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer Emerging Role of Topotecan in First-Line Therapy of Small-Cell Lung Cancer A review of first-line treatment for small-cell lung cancer A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer Management of small cell lung cancer [Small cell lung cancer--state of the art and future perspectives]. Novel systemic therapies for small cell lung cancer Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer Chemotherapy for small cell lung cancer: a comprehensive review Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial Small cell lung cancer: past, present, and future Recent advances in cancer chemotherapy The role of anthracyclines in small cell lung cancer Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases Chemotherapy as treatment of primary and recurrent small cell lung cancer Topoisomerase I targeting agents in small-cell lung cancer Progress in the therapy of small cell lung cancer

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software